Executive Summary
For sponsors developing lipid nanoparticle (LNP) RNA therapeutics, defining the in vivo biodistribution profile is a core component of the regulatory submission package for both Investigational New Drug (IND) and Investigational Medicinal Product Dossier (IMPD) applications. A standard template does not exist; a tailored, data-driven strategy is required to characterize the distribution of both the LNP carrier and the RNA payload across target and non-target tissues. This informs the definitive toxicology program, establishes potential liabilities, and provides the mechanistic data required by global regulatory bodies. Our approach integrates quantitative molecular assays with advanced histological techniques to build a comprehensive data package that supports an accelerated 18-24 month timeline to IND.
Frequently Asked Questions
Q: What are the key considerations for designing IND-enabling biodistribution studies for an LNP therapy?
The primary considerations involve designing a study that can independently track the lipid components and the RNA payload. This requires orthogonal analytical methods, such as LC-MS for lipids and RT-qPCR for RNA, to understand if they dissociate post-administration. The study must also cover a sufficient time course to evaluate both initial distribution and subsequent clearance from tissues, which is a focus for agencies like the FDA and EMA.
Q: How do GxP conditions apply to LNP biodistribution studies for submissions in Germany and the EU?
For IMPD submissions to European authorities, biodistribution studies that support the definitive toxicology program must be conducted under GLP conditions. This ensures data integrity, reproducibility, and traceability. Within our >100,000 sq ft facilities, Franklin Biolabs conducts these IND-enabling studies in GLP-compliant environments to generate data packages that meet the stringent requirements for both FDA and EU submissions. `
`
Q: Why is a nonhuman primate (NHP) model sometimes required for LNP biodistribution ahead of clinical trials?
While rodent models are standard, NHP models may be necessary when the LNP formulation or RNA target has a potential for species-specific interactions, particularly concerning the immune system or specific cell-surface receptors. An NHP model provides a more translationally relevant system to assess biodistribution in a complex organism with an immune profile that more closely mirrors the human response.
Tailored Biodistribution Strategies for RNA Therapeutics
The biodistribution profile of an LNP-based therapeutic is a function of its unique physicochemical properties: particle size, surface charge, and the specific composition of its ionizable and helper lipids. These factors dictate tissue uptake, particularly in the liver, spleen, and lymphoid organs. A robust preclinical program quantifies the concentration and persistence of the RNA payload and lipid excipients in a comprehensive panel of tissues over time.
Our scientific team designs and executes these IND-enabling toxicology studies with a focus on regulatory expectations. We develop and qualify phase-appropriate bioanalytical methods to provide precise quantification, supporting programs from early proof-of-concept to GxP-compliant safety assessment. This detailed characterization is necessary for interpreting toxicology findings and establishing a safe starting dose for first-in-human trials.
Integrating Molecular and Histological Endpoints
A complete biodistribution data package relies on multiple, complementary analytical techniques. A multi-faceted approach provides a more complete picture for regulatory review.
-
Quantitative Analysis (RT-qPCR): Provides sensitive measurement of RNA payload concentration in tissue homogenates, establishing key pharmacokinetic parameters.
-
Histology and In Situ Hybridization (ISH): Offers cellular-level resolution, identifying specific cell types that take up the LNP and express the RNA payload. This is necessary for correlating biodistribution with potential on-target efficacy or non-target tissue toxicological findings.
This dual methodology reflects the technical approach used in our collaboration with Moderna and is a core component of our work. By understanding where a therapeutic goes and for how long, we directly inform the clinical risk assessment. The translational impact of precise delivery is clear in studies evaluating LNP-mRNA therapies for rare metabolic disorders, where effective delivery to the target tissue resulted in a durable correction of the disease phenotype in an animal model (PMID: 36936447).
Franklin Biolabs provides the integrated expertise to execute these complex studies. Our approach is built on the scientific leadership and core team whose work has contributed to a 100% successful IND rate since 2019, a track record established prior to our formal launch in 2024. This deep experience in developing next-generation therapies is detailed further in our parent Preclinical | Translational Services hub.
